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*The Use and Efficacy of Mucolytic Agents
C. BENJAMIN, (STAATSEXAMEN, SWITZERLM'D), K!erksdorp Hospital, Tv!
SUMMARY
A total of 100 patients were tested with different mucolytic
agents. In patients with acute obstructive airway disease
pancreatic dornase and acetyl-L-cysteine (Airbron) showed
excellent mucolytic activity. With Alevaire and Ascoxal we
were unable to demonstrate any mucolytic action. Pro-
teolytic enzymes were not tested in view of ~heir uncon-
trollable action on alveolar epithelium and the recent ob-
servation that metaplasia of the bronchial mucosa may
be produced by these enzymes.
S. Afr. Med. l., 45, 948 (1971).
NATURE AND COMPOSITION OF
BRONCHIAL SECRETION
Normal human bronchial mucus is a semiviscid substance
composed almost entirely of mucoprotein and mucopoly-
saccharide fibres.' Its main function appears to be that of
trapping and removing foreign particles within the airway,
as well as for moistening the bronchial mucosa. It is
produced by the bronchial glands in the trachea and
bronchi and by goblet cells in the epithelium of these
airways.
In acute or chronic bronchitis there is a marked increase
in the number and size of mucus glands and in tbe number
of goblet cells. When infection occurs tbe mucus fibres
fragment and are replaced by fibres of deoxyribonucleic
acid (DNA).'" DNA is present in purulent sputum because
of cellular and tissue breakdown and is not found in the
original mucus secretion. The presence of DNA signifi-
cantly increases the viscosity of sputum and inhibits the
lysis of sputum by leukocytic proteases. The purulence of
sputum can usually be controlled by suitable antibiotics,
but the viscosity and amount of mucoid sputum is not
reduced by antibiotics:
Mucus flow and removal of sputum becomes a problem
when the rate of mucus production is excessive, when its
viscosity interferes with normal ciliary movement, or when
infection results in an excessive amount (e.g. in bronchial
asthma, postoperatively, etc.). Patients with lung abscesses,
bronchiectasis and especially those with cystic fibrosis have
this type of involvement.
The purpose of this article is to demonstrate the efficacy
of certain well known, widely advertised mucolytic agents.
The indications and contra-indications for their use will
be discussed.
~Daie received: 19 April 1971.
METHODS AND MATERIALS
In Vitro Tests
Specimens of purulent and mucoid sputum from patients
with chronic chest disease were collected in test tubes. A
few drops of the mucolytic agent to be tested were mixed
with approximately 2 ml of sputum. The result was read
macroscopically after t hour as follows: (i) sputum com-
pletely dissolved 100 %; (ii) sputum partially dissolved
± 50 %; and (iii) sputum not dissolved 0 %.
In Vivo Tests
The expiratory volume was measured with a Wright peak
flow meter. A maximum expiratory flow was taken before
starting the treatment and 3 readings were taken at to, 2-
and 4-hour intervals. Finally the total expectoration was
measured after 4 hours.
The patients for the study were separated into 2 groups:
The first group of patients (group A) exhibited minor
pulmonary diseases which included pneumonitis, acute or
chronic bronchitis and bronchopneumonia.
The second group of patients (group B) had a variety of
pulmonary diseases which included silicosis, pulmonary
emphysema, obstructive airway diseases, as well as bron-
chial carcinoma and pulmonary tuberculosis. The apparatus
we used for the nebulization of the different aerosols by
oxygen was a Bird Mark 8 machine. This machine pro-
duces a mist with a particle size of 0·5 - 3·0 p.; the inspi-
ratory flow rate, inspiratory pressure, the expiratory flow
rate (retarded or accelerated) and the length of the ex-




Description: Deanase is a deoxyribonuclease extracted
from the pancreas.
Action: The higWy polymerized nucleic acids or poly-
nUcleotides, as they exist in the human sputum, are broken
down into smaller components (oligonucleotides) by the
action of specific enzymes.' Deoxyribonuclease (DNAse)
reacts on the bond of deoxyribonucleic acid (DNA), and
this reaction is catalysed in the presence of the activator
Mg++.' This enzymatic reaction causes an irreversible
reduction in the viscosity of the sputum.
*Keatings Pharmaceuticals Ltd, Johannesburg.
d
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TABLE I. RESULTS OF ADMINISTRATION OF 50000 U DEAN ASE TO 31 PATIENTS
949
Maximum expiratory flow Vitro- Total
Patient test expectoration
No. Age Diagnosis Before Y2 hr 2 hrs 4 hrs % in 4 hrs Cml) Additional medication
Group A-Patients with minor pulmonary diseases
1 24 Pneumonitis 309 316 342 357 100 289 Penbritin
2 27 Pneumonitis 300 308 315 328 100 198 Penbritin
3 34 Pneumonitis 283 291 317 325 100 124 Chloramphenicol
4 45 Pneumonitis 281 289 297 311 100 130 Ery:hromycin
5 79 Pneumonitis 141 152 163 182 100 156 Chloramphenicol
6 87 Pneumonitis 73 87 108 143 100 416 Chloramphenicol
7 63 Chr. bronchitis 367 382 386 390 100 121 Bactrim
8 57 Chr. bronchitis 348 359 367 371 100 149 Bactrim
9 49 Chr. bronchitis 319 322 329 335 100 108 Bactrim
10 67 Chr. bronchitis 245 249 261 268 100 111 Erythromycin
11 73 Chr. bronchitis 195 208 212 267 100 380 Chloramphenicol
12 57 Bronchial asthma + inf. 209 219 227 230 100 137 Aminophyllin + Bactrim
13 47 Bronchial asthma + inf. 200 211 218 243 100 103 Aminophyllin + Bactrim
14 50 Bronchial asthma + inf. 134 137 158 162 100 167 Aminophyllin
Group B-Patients with a variety of pulmonary diseases
1 49 Bronchiectasis + inf." 98 109 111 119 100 348
2 57 Bronchiectasis + inf. 101 123 129 145 100 283
3 65 Bronchiectasis + inf. 125 131 147 145 100 208
4 73 Bronchiectasis + inf. 157 164 169 174 100 178
5 61 Silicosis + bronchitis 92 108 110 118 100 248 Bactrim
6 63 Silicosis + bronchitis 167 171 178 181 100 161 Bactrim
7 70 Silicosis + bronchitis 180 192 192 195 100 104 Erythromycin
8 54 Pulm. emphysema + br. 90 93 97 109 100 359 Chloramphenicol
9 72 Pulm. emphysema + br. 131 139 141 143 100 209 Ceporan
10 71 Cor pulmonale + br. 161 170 172 179 100 150 Bactrim
11 80 Cor pulmonale + br. 165 167 170 175 100 100 Chloramphenicol
12 ';5 Pulm. TB + chr. br. 231 235 238 240 100 191 INH, PAS, streptomycin
13 50 Pulm. TB + chr. br. 308 311 321 320 100 92 INH, PAS, streptomycin
14 55 Pulm. TB + emphysema 56 63 71 75 100 131 INH, PAS, streptomycin
Aminophyllin
15 34 Emphysema + chr.
bronchial asthma 108 109 121 127 100 172 Aminophyllin
16 45 Lymphangitis carcinoma 78 82 89 92 100 123 Cyclophosphamide
17 65 Interstitial pneumonitis 67 71 76 85 100 131 Chloramphenicol
• Slight haemoptysis.
The effect of DNA upon respiratory secretion is des-
cribed as follows: It (i) increases sputum viscosity; (ii)
protects protein in nucleoprotein complexes from enzy-
matic proteolysis; (iii) inhibits proteolytic enzymes directly
and (iv) reduces effectiveness of certain basic antibiotics."
Administration and Dosage: In the following test
(Table I) on 31 patients we used 50000 U of Deanase for
each nebulization and pure oxygen was used as the
vehicle. Deanase was dissolved in a sterile 2°~ magnesium
sulphate solution.
Comment
After administration of dornase a massive liquefaction
of mucus takes place. The cough is greatly increased and
becomes very productive. After a single administration of
50000 U dornase the excretion of mucus up to 600 ml was
observed.
Dornase can be mixed with antibiotics, except basic
types, and with a bronchodilator in appropriate concen-
tration." The enzyme can be used effectively in either 10°"
propylene glycol or saline diluent with the addition of
Mg-+. Propylene glycol is preferred as it provides a sooth-
ing effect on the tracheobronchial tree and eases the mobili-
zation of respiratory secretion.
In the abovementioned investigations dornase proved to
be an effective mucolytic agent for the mobilization of
mucus. Tn both series the patients were aware of increased
air entry after inhalation which corresponded with the
obtained MPF readings. In group B the results obtained
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TABLE 11. RESULTS OF ADMINISTRATION OF 3 ml AIRBRON
Maximum expiratory flow Vitro- Total
Patient test expectoration
No. Age Diagnosis Before Y2 hr 2 hrs 4 hrs % in 4 hrs Cml) _ Additional medication
Group A-Patients with minor pulmonary diseases
1 33 Pneumonitis 357 361 372 385 100 167 Bactrim
2 35 Pneumonitis 292 305 313 338 100 260 Bactrim
3 41 Pneumonitis 290 295 300 331 100 218 Keflin
4 46 Pneumonitis 185 196 232 246 100 279 Keflin
5 74 Pneumonitis 97 114 168 191 100 410 Chloramphenicol
6 81 Pneumonitis 87 92 96 105 100 421 Chloramphenicol
7 64 Chr. bronchitis 234 241 253 263 100 171 Bactrim
8 67 Chr. bronchitis 208 222 235 240 100 197 Erythromycin
9 69 Chr. bronchitis 72 75 82 91 100 82 Bactrim
10 73 Chr. bronchitis 66 69 72 78 100 61 Erythromycin
11 80 Chr. bronchitis 65 69 71 82 100 115 Bactrim
12 62 Inf. bronchial asthma 288 293 298 314 100 306 Bactrim + Aminophyllin
13 65 Inf. bronchial asthma 263 270 284 295 100 255 Keflin + Aminophyllin
14 70 Inf. bronchial asthma 197 196 203 212 100 214 Bactrim + Aminophyllin
15 79 Inf. bronchial asthma 110 115 127 131 100 150 Bactrim + Aminophyllin
Group B-Patients with a variety of pulmonary diseases
1 36 Pulm. emphysema 110 115 113 123 100 97
2 42 Pulm. emphysema 201 225 223 219 100 82 Erythromycin
3 54 Pulm. emphysema 218 223 230 230 100 121
4 67 Pulm. emphysema 247 249 253 252 100 105 Bactrim
5 79 Pulm. emphysema 94 98 98 101 100 45
6 44 Bronchitis + silicosis 139 140 139 141 100 62 Chloramphenicol
7 49 Bronchitis + silicosis 211 218 239 239 100 211 Chloramphenicol
8 59 Bronchitis + silicosis 101 109 107 108 100 108 Bactrim
9 84 Bronchitis + silicosis 98 98 99 102 100 37 Erythromycin
10 62 Cor Pulmonale 123 127 129 135 100 111 Heparin
11 64 Cor Pulmonale 138 138 145 146 100 78 Heparin + Bactrim
12 45 Pulm. TB + pneumonitis 74 78 87 89 100 123 INH, PAS, streptomycin
13 55 Pulm. TB + bronchitis 178 182 187 193 100 201 INH, PAS, streptomycin
14 66 Pum. TB + lung abcess 62 67 130 149 100 372 INH, PAS, streptomycin
15 45 Scleroderma + chr. Chloramphenicol +
bronchitis 95 103 109 111 100 231 peripheral vasodilators
16 69 Silicosis + emphysema Chloramphenicol +
+ pneumonia 57 60 67 93 100 182 Aminophyllin
were on the average slightly better. Dornase showed no
mucolytic activity in normal respiratory secretion.
Side-Effects
The side-effects seen during dornase therapy have been
few and minor. In some patients a soreness of the posterior
pharynx developed. This can be prevented by having them
gargle with water immediately after each treatment to
remove the enzyme from the pharyngeal mucosa~
In one of the patients a slight haemoptysis occurred.
This may have been related to the advanced bronchiectasis
from which the patient suffered.
Airbront
Description: N-acetyl-L-cysteine 20% in sterile aqueous
solution.
Action: The action of Airbron probably depends on the
presence of a free sulphydryl group which acts upon the
disuIfide bonds of mucoprotein and mucopolysaccharide.
Deoxyribonucleic acid is also decomposed by L-cysteine:
This action depends on:' (a) pH (the optimum lies
between 7·0 and 9-0), (b) the positive pressure breathing
(IPPB) and (c) the concentration.
The activity of L-cysteine is completely lost by a thou-
sandfold dilution of the commercial 20% materiaL'
tB.D.H. (Ply) Lld, Johannesburg.
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Administration: The apparatus used for the inhalation
of L-cysteine should be of glass or plastic as metals and
rubber react with the drug. The one we used was the
'Agla' all-glass device (BuIToughs Wellcome).
The commercial distributors do not recommend oxygen
as a vehicle. It has been reported that high oxygen con-
centration rapidly inactivates L-cysteine;T the commercial
preparation contains ethylene diamine tetracetic acid
(EDTA) to prevent oxidation and therefore the use of
oxygen for nebulization is not contra-indicated.'
Dosage: Depending on the tolerance of the patient 3 ml
of 10 or 20% Airbron solution up to 4 times a day is
recommended. In the following tests (Table ll) we used
3 ml of 20~~ solution of Airbron for each nebulization.
Pure oxygen was used as the vehicle.
Comment and Side-Effects
N-acetyl-L-cysteine was effective in both purulent and
nonpurulent (mucoid) sputums. In group A, a generalized
improvement of the respiratory functions was found. In
group B, a reduction in cough and sputum production was
noted. The sputum viscosity was considerably reduced
and also the colour was clearer.
However, the results that we obtained in group B were
not so impressive as they were in the first group. This may
be due to the advanced pulmonary pathology of the
patients.
Airbron does not have a very pleasant smell and may on
occasion cause bronchospasm. The addition of Isuprel or
other bronchodilator is recommended. If bronchodilators
do not reverse the bronchoconstrictive effects, it may be
necessary to discontinue the medication: The irritant effect
of L-cysteine in the bronchi is probably due to its hyper-
tonicity and can be prevented by combining the aerosol
with a local anaesthetic (lignocaine hydrochloride 4%,
amethocaine hydrochloride 2% or cocaine hydrochloride
10%).
It was also reported that L-cysteine inactivates a number
of antibiotics (e.g. all the penicillin types).' .
During this trial 2 patients reacted to Airbron with
stomatitis, 3 with nausea and vomiting. Dyspnoea, wheez-
ing, feverfi hoarseness or nasal and eyelid irritation as re-
ported by Robinson f.?t al." occurred in my series. Broncho-
spasm has been reported' but did not occur in any of our
patients.
Alevairet
Description: Alevaire is an alkaline solution containing
superinone 0·125 %, sodium bicarbonate 2 % and glycerine
5%.
Action: It stabilizes aerosol droplets and allows more
effective hydration of the respiratory secretion by lower-
ing the surface tension. This action is dependent on the
positive pressure breathing (IPPB) and on the effective
concentration of aerosol penetrating into the lungs:
Administration: Twenty-four patients with different
pulmonary diseases were divided into 2 similar groups.
Group A was treated with 5 ml Alevaire using oxygen as
the vehicle. Group B was treated with 2% solution of
sodium bicarbonate-,-5 ml solution and oxygen were used.
Comment
Our trial showed that Alevaire is not more effective than
the control solution containing bicarbonate. In vitro neither
purulent nor mucoid sputum was liquefied and none of the
patients experienced subjective improvement after Alevaire
inhalation.
We are of the opinion that the administration of Alevaire
alone has no value which confirms the results of previous
studies.',<.12
tWinthrop, Durban.
TABLE Ill. RESULTS OF ADMINISTRATION OF 5 ml ALEVAIRE
Maximum expiratory flow Vitro- Total
Patient test expectoration
No. Age Diagnosis Before 1,12 hr 2 hrs 4 hrs % in 4 hrs Cml) Additional medication
1 51 Chr. bronchitis 234 212 208 230 0 12
2 62 Chr. bronchitis 317 317 316 318 0 19
3 75 Chr. bronchitis 195 195 196 195 0 15
4 41 Pneumonitis 340 358 347 352 0 31 Penbritin
5 48 Pneumonitis 351 350 352 350 0 28 Chloramphenicol
6 57 Bronchiectasis 159 156 158 157 0 5
7 57 Pulm. TB 259 234 240 251 0 13 INH, PAS, streptomycin
8 67 Sarcoidosis 208 206 207 209 0 17 INH, PAS, streptomycin
9 74 Silicosis 189 191 190 190 0 0 Nethaprin Dospan
10 38 Silicosis 215 218 219 217 0 0
11 44 .Pulm. emphysema 159 156 157 158 0 9
12 71 Ca-bronchus 91 95 94 92 0 2 Cyclophosphamide
J
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TABLE IV. RESULTS OF TREATMENT WITH 5 ml SODIUM BICARBONATE SOLUTION
Mid-expiratory peak flow Vitro- Total
Patient test expectoration
No. Age Diagnosis Before Y2 hr 2 hrs 4 hrs % in 4 hrs Cml) Additional medication
1 42 Chr. bronchitis 222 225 223 223 0 5
2 48 Chr. bronchitis 314 311 312 313 0 7
3 57 Chr. bronchitis 323 320 321 321 0 12
4 67 Chr. bronchitis 300 300 299 298 0 10
5 32 Pneumonitis 248 249 247 248 0 19 Bactrim
6 39 Pneumonitis 375 372 374 376 0 21 Erythromycin
7 47 Pneumonitis 402 404 401 406 0 31 Erythromycin
8 53 Pneumonitis 391 390 391 392 0 23 Chloramphenicol
9 62 Silicosis 223 209 211 219 0 4 Aminophyllin + Bactrim
10 73 Silicosis 189 187 185 188 0 2 Aminophyllin
11 37 'Bronchiectasis 321 320 325 322 0 0 Bactrim
12 42 Pulm. TB 241 236 239 240 0 4 INH, PAS, streptomycin
Proteolytic Enzymes
. A. Trypsin preparations (Tryptar,* Trypure,t Trypse-
vact).
B. Alpha, delta-chymotrypsin preparations (Chymar,*
Chymovact).
These are enzymes which catalyse the cleavage of peptide
bonds: In vitro the proteolytic enzymes 'showed an effective
mucolytic activity in liquefying purulent and nonpurulent .
sputum. But the observation of metaplasia in the bronchial
mucosa led some to fear that proteolytic enzyme aerosols
might be carcinogenic, and their use declined considerably:
Recent observations suggest that the use of any proteolytic
enzyme aerosols may be dangerous; lung tissue may be
digested and the development of emphysema accelerated
as a result. Also severe haemoptysis may occur. These
agents should only be used with prior evaluation of the
antitrypsin status of the patient in view of the high fre-
quency of alpha,-antitrypsin deficiency in patients with
chest disease:
Tromasinl1
Tromasin is a purified and standardized extract of pro-
teolytic enzymes from the unripe fruit of the Carica papaya
plant. This enzyme is not inhibited by the blood or lung
tissues of man and certain animals, and may be dangerous
when used as an aeroso!." Inhalation of aerosolized papain
is an experimental means for producing anatomic emphy-
sema in animals, and it probably owes its success to the
lack of innate inhibitors in blood and tissues.
Streptokinase-Streptodornase (Varidase§)
Streptodornase is a deoxyribonuclease-containing enzyme
found in certain streptococci. Streptokinase is an activator
of plasminogen (profibrinolysin) and is derived from certain
haemolytic streptococci.
Streptodornase (dornase) has already been discussed.
Streptokinase has not demonstrated any mucolytic activity.
*Armour Pharmaceuticals Ltd, Johannesburg.
tNovo Industries Pharmaceuticals. Johannesburg.
tKeatings Pharmaceuticals Ltd. Johannesburg.
~Warner Pharmaceuticals (pty) Ltd, Johannesburg.
§Lederle (Pty) Ltd, Johannesburg.
However, it acts indirectly upon a substrate of fibrin or
fibrinogen by activating a fibrinolytic enzyme in the human
serum. The activation of this fibrinolytic system brings a
rapid dissolution of blood clots and their fibrinous por-
tions." Theoretically this would mean that: (i) strepto-
dornase does influence the sputum viscosity; and (ii) strep-
tokinase has an effect on the fibrotic pulmonary tissue.
This fibrinolytic action in the lungs must be controlled.
The accumulated tissue fluid must be drained and aspirated,
especially in closed spaces; this is because streptokinase
may cause a localized leucocytosis and in the presence of
infection a lung abscess could result. l1
In view of the above reasons this preparation may be
extremely dangerous if administered as an aerosol.
Ascoxalt
Ascoxal (sodium percarbonate 70 mg, copper sulphate
0·2 mg, ascorbic acid 100 mg) is used as a mucolytic agent
and Palmer12 initially described its excellent mucolytic
properties. However, in a subsequent article Palmer13
reported that this compound failed to demonstrate any
mucolytic activity.
In our experiments we used a concentrated Ascoxal
solution, prepared from 2 tablets, dissolved in 4 ml water
and given by aerosol inhalation.
We were unable to demonstrate any mucolytic action.
Ascoxal is no more effective than a control solution
containing water only.
I wish to thank Dr M. Marais, Medical Superintendent of the
Klerksdorp Hospital, for permission to publish this report and
Dr A. Frame for his assistance.
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